| FDG PET For Assessment of Therapeutic Response DOWNLOAD FACT SHEET IN PDF References: 1) Shankar LK, Hoffman JM, Bacharach S. Consensus Recommendations for the Use of 18F-FDG PET as an Indicator of Therapeutic Response in Patients in National Cancer Institute Trials. The Journal of Nuclear Medicine 2006;47(6):1059-1066 [PDF] 2) Young H, Baum R, Cremerius U. Measurement of Clinical and Subclinical Tumour Response Using [18F]-fluorodeoxyglucose and Positron Emission Tomography: Review and 1999 EORTC Recommendations. European Journal of Cancer 1999;35(13):1773-1782 [PDF] 3) Wahl RL, Jacene H, Kasamon Y. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors. J Nucl Med 2009;50:122S-150S [PDF] 4) Ghosh P, Kelly M. Expanding the Power of PET with PERCIST. Accessed at http://www.medical.siemens.com/siemens/en_US/gg_nm_FBAs/files/whtpap/wp_10_percist.pdf on 3/17/2012 [PDF] |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |